AFAya Fujishiro

Aya Fujishiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aya Fujishiro has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Akifumi Takaori-Kondo

    Department of Hematology and Oncology, Kyoto University Graduate School for Medicine, Kyoto, Japan

    2 shared publications
  • Akira Andoh

    Division of Gastroenterology and Hematology, Department of Medicine, Shiga University of Medical Science, Otsu, Japan

    2 shared publications
  • Kaoru Tohyama

    Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan

    2 shared publications
  • Masaki Iwasa

    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan

    2 shared publications
  • Sumie Fujii

    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan

    2 shared publications
  • Taira Maekawa

    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan

    2 shared publications

Latest Publications

  • Correction to: Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells

    by Aya Fujishiro, Masaki Iwasa, Sumie Fujii, Taira Maekawa, Akira Andoh, Kaoru Tohyama, Akifumi Takaori-Kondo, Yasuo Miura

    In the original publication of the article, the Figs. 4 C, F and 5 B, C were published with unexpected appearance of dots.

  • Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells

    by Aya Fujishiro, Masaki Iwasa, Sumie Fujii, Taira Maekawa, Akira Andoh, Kaoru Tohyama, Akifumi Takaori-Kondo, Yasuo Miura

    Vitamin K2 in the form of menatetrenone has clinical benefits for osteoporosis and cytopenia. Given the dominant role of mesenchymal-osteolineage cells in the regulation of hematopoiesis, we investigated whether menatetrenone alters the hematopoiesis-supportive capability of human bone marrow mesenchymal stromal/stem cells (BM-MSCs). Menatetrenone up-regulated fibronectin protein expression in BM-MSCs without affecting their proliferation and differentiation capabilities. In addition, menatetrenone treatment of BM-MSCs enhanced generation of the CD34+ cell population in co-cultures through acceleration of the cell cycle. This effect was associated with cell–cell interactions mediated by VLA-4 and fibronectin. This proposal was supported by cytokine array and quantitative real-time PCR analyses, in which there were no significant differences between the expression levels of hematopoiesis-associated soluble factors in naïve and menatetrenone-treated BM-MSCs. Profiling of hematopoietic cells in co-cultures with menatetrenone-treated BM-MSCs demonstrated that they included significantly more CD34+CD38+ hematopoietic progenitor cells and cells skewed toward myeloid and megakaryocytic lineages than those in co-cultures with untreated BM-MSCs. Notably, myelodysplastic syndrome-derived cells were induced to undergo apoptosis when co-cultured with BM-MSCs, and this effect was enhanced by menatetrenone. Overall, our findings indicate that pharmacological treatment with menatetrenone bestows a unique hematopoiesis-supportive capability on BM-MSCs, which may contribute to the clinical improvement of cytopenia.